Summit Therapeutics Inc. — Director's Dealing 2024

Aug 23, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-08-23

Reporting Person: Soni Manmeet Singh (Director, COO and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-23	Performance Stock Option (right to buy)	$1.68	A	2800000	Acquired	2033-10-13	Common Stock (2800000)	Direct

Footnotes

F1: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 11,200,000 shares underlying options which were granted on October 13, 2023 that remain subject to the satisfaction of performance conditions.

F2: Not applicable.